We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies. Close

Regeneron; Pfizer hit with Covid-19 therapeutic suits

Intellectual Property Magazine

Regeneron; Pfizer hit with Covid-19 therapeutic suits

‘Gold standard’ reagent technology used totreat Covid-19 subject of suit against pharmagiants

A San-Diego based therapeutics firm is suing Regeneron,Pfizer and BioNTech over the alleged infringements of a reagent used intherapeutics aimed at fighting Covid-19.

The rest of this document is only available to i-law.com online subscribers.

If you are already a subscriber, please enter your details below to log in.

Enter your email address to log in as a user on your corporate account.
Remember me on this computer

Not yet an i-law subscriber?


Request a trial Find out more